Last reviewed · How we verify
the third batch vaccine
the third batch vaccine is a vaccine Biologic drug developed by Beijing Chaoyang District Centre for Disease Control and Prevention. It is currently FDA-approved.
This vaccine stimulates the immune system to recognize and respond to specific pathogens or disease antigens.
The third batch vaccine is being studied for its safety, consistency, and immunity duration in children aged 6-71 months. It is a post-marketing inactivated Enterovirus Type 71 (EV71) vaccine, which induces an immune response through its biological vaccine component.
At a glance
| Generic name | the third batch vaccine |
|---|---|
| Sponsor | Beijing Chaoyang District Centre for Disease Control and Prevention |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Vaccines work by introducing a weakened or inactivated form of a pathogen, or its antigenic components, to train the adaptive immune system to produce antibodies and cellular immunity. Upon subsequent exposure to the actual pathogen, the primed immune system can mount a rapid and effective response to prevent or reduce disease severity.
Approved indications
Common side effects
- Local injection site reactions (pain, redness, swelling)
- Fever
- Fatigue
Key clinical trials
- Clinical Trial for Batch Consistency of EV71 Vaccine (PHASE4)
- Phase II/III Randomized Clinical Trial of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine (PHASE2, PHASE3)
- Consistency Study for Three Commercial Lots of Inactivated Poliomyelitis Vaccine Made From Sabin Strain (PHASE4)
- Immunity and Safety of Inactivated Enterovirus 71 Vaccine Post-marketing Among Children Aged 6-35 Months in China (PHASE4)
- Safety, Three Batches Consistency and Immunity Duration of the Post-marketing Inactivated Enterovirus Type 71 (EV71) Vaccine in Children Aged 6-71 Months (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- the third batch vaccine CI brief — competitive landscape report
- the third batch vaccine updates RSS · CI watch RSS
- Beijing Chaoyang District Centre for Disease Control and Prevention portfolio CI
Frequently asked questions about the third batch vaccine
What is the third batch vaccine?
How does the third batch vaccine work?
Who makes the third batch vaccine?
What drug class is the third batch vaccine in?
What development phase is the third batch vaccine in?
What are the side effects of the third batch vaccine?
Related
- Drug class: All vaccine drugs
- Manufacturer: Beijing Chaoyang District Centre for Disease Control and Prevention — full pipeline
- Therapeutic area: All drugs in Immunology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing